Search Medical Condition
Please enter condition
Please choose location

Warsazawa, Poland Clinical Trials

A listing of Warsazawa, Poland clinical trials actively recruiting patients volunteers.

RESULTS

Found (387) clinical trials

A Phase I/II Open-Label Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

Patients will be recruited into cohorts, with a minimum of three and a maximum of six patients per cohort. All patients at a given dose level must complete Cycle 1 (3 week period) before escalation in subsequent patients can proceed. The decision for dose escalation to the next dose level ...

Phase

0.0 miles

Learn More »

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall

Patients who will be allocated in arm A, will receive a single intratumor injection of NBTXR3 and will receive external beam radiotherapy starting 24hrs after the injection up to completion of 5 weeks, 5 days a week of treatment (50Gy, 2Gy/fraction). Then, all patients will undergo surgical resection of the ...

Phase

0.0 miles

Learn More »

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Evaluating efficacy & safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug administration is 28 weeks. Eligible subjects may ...

Phase

0.0 miles

Learn More »

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

Patients, all planned for nephrectomy, will be stratified according to the Heng risk criteria (36 high risk patients, 54 intermediate risk patients) and randomized in a 2:1 ratio to receive Intuvax+ Sunitinib or Sunitinib alone. Two doses of Intuvax will be administered in to the primary tumour before nephrectomy. The ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)

The aim of the study is to assess the efficacy of HepaStem treatment in paediatric patients suffering from urea cycle disorders.

Phase

0.0 miles

Learn More »

Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.

Phase

0.0 miles

Learn More »

Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)

The purpose of this trial is to investigate the safety and efficacy of mesalamine 2 g extended release granules (sachet) once a day (QD) for maintenance of clinical and endoscopic remission in subjects with UC. The duration of treatment for each subject will be 6 months.

Phase

0.0 miles

Learn More »

Dose Optimization Study of Idelalisib in Follicular Lymphoma

This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.

Phase

0.0 miles

Learn More »

IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

This is a multicentre, placebo-controlled, double-blind, 1:1 randomised Phase IIb study in female hormone receptor-positive metastatic breast cancer patients. The study comprises of two stages. Stage 1 is the open-label, safety run-in stage consisting of cohort 1 and 2 to confirm the (RPTD) of IMP321 in combination with paclitaxel. Stage ...

Phase

0.0 miles

Learn More »

Study of IFN-K in Systemic Lupus Erythematosus

The safety and immunogenicity of the IFN-Kinoid (IFN-K) have been evaluated in a phase I clinical study conducted in subjects with SLE. Preliminary results were promising. The principal aim of the present study is to confirm the neutralization of the interferon gene signature and the clinical efficacy of IFN-K in ...

Phase

0.0 miles

Learn More »